Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect
Erica Salvati, … , Gabriella Zupi, Annamaria Biroccio
Erica Salvati, … , Gabriella Zupi, Annamaria Biroccio
Published October 11, 2007
Citation Information: J Clin Invest. 2007;117(11):3236-3247. https://doi.org/10.1172/JCI32461.
View: Text | PDF
Research Article

Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect

  • Text
  • PDF
Abstract

Functional telomeres are required for the replicability of cancer cells. The G-rich strand of telomeric DNA can fold into a 4-stranded structure known as the G-quadruplex (G4), whose stabilization alters telomere function limiting cancer cell growth. Therefore, the G4 ligand RHPS4 may possess antitumor activity. Here, we show that RHPS4 triggers a rapid and potent DNA damage response at telomeres in human transformed fibroblasts and melanoma cells, characterized by the formation of several telomeric foci containing phosphorylated DNA damage response factors γ-H2AX, RAD17, and 53BP1. This was dependent on DNA repair enzyme ATR, correlated with delocalization of the protective telomeric DNA–binding protein POT1, and was antagonized by overexpression of POT1 or TRF2. In mice, RHPS4 exerted its antitumor effect on xenografts of human tumor cells of different histotype by telomere injury and tumor cell apoptosis. Tumor inhibition was accompanied by a strong DNA damage response, and tumors overexpressing POT1 or TRF2 were resistant to RHPS4 treatment. These data provide evidence that RHPS4 is a telomere damage inducer and that telomere disruption selectively triggered in malignant cells results in a high therapeutic index in mice. They also define a functional link between telomere damage and antitumor activity and reveal the key role of telomere-protective factors TRF2 and POT1 in response to this anti-telomere strategy.

Authors

Erica Salvati, Carlo Leonetti, Angela Rizzo, Marco Scarsella, Marcella Mottolese, Rossella Galati, Isabella Sperduti, Malcolm F.G. Stevens, Maurizio D’Incalci, Maria Blasco, Giovanna Chiorino, Serge Bauwens, Béatrice Horard, Eric Gilson, Antonella Stoppacciaro, Gabriella Zupi, Annamaria Biroccio

×

Figure 1

RHPS4 induces phosphorylation of H2AX in transformed and tumor cells.

Options: View larger image (or click on image) Download as PowerPoint
RHPS4 induces phosphorylation of H2AX in transformed and tumor cells.
(A...
(A) Human transformed BJ-EHLT and M14 melanoma cells were treated with RHPS4 for 4 days. At the indicated times, cells were counted and the viability determined. The data represent the number of untreated (filled squares) and RHPS4-treated cells (open squares) during the growth in culture. The mean of 3 independent experiments with comparable results is shown. Error bars indicate SD. (B) Percentage of cells containing γ-H2AX foci (upper panel) and Western blot analysis (lower panel) of γ-H2AX in BJ-EHLT and M14 cells treated with RHPS4 for the indicated times. γ-H2AX foci were quantified using mouse mAbs and rabbit pAbs. On average, more than 200 cells were screened per time point in 3 independent experiments. Error bars indicate SD. The levels of H2A were used as loading control. (C) Representative immunofluorescence images of BJ-EHLT and M14 cells treated with RHPS4 for 8 hours. Original magnification, ×40.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts